Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkem LaboratoriesNSE:ALKEM -1.17%96 3-Year EBITDA Growth Rate is 25.40% as of Jun. 2026, which is 55% above its 10-year median of 16.40. GuruFocus rates NSE:ALKEM with a GF Score™ of 96/100 and a GF Value™ of ₹6,209.31 (Modestly Undervalued). Among 807 Drug Manufacturers companies, Alkem Laboratories ranks better than 74.1% on this metric.
During the past 12 months, Alkem Laboratories's average EBITDA Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alkem Laboratories was 30.20% per year. The lowest was 2.90% per year. And the median was 16.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alkem Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:ALKEM vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkem Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alkem Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.40% mean?
Alkem Laboratories (NSE:ALKEM) has a 3-Year EBITDA Growth Rate of 25.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alkem Laboratories and its competitors. This is 55% above median its historical median of 16.40. Over the past decade, Alkem Laboratories' 3-Year EBITDA Growth Rate has ranged from 2.90 to 30.20. According to the industry distribution chart, Alkem Laboratories ranks #209 out of 807 companies in the Drug Manufacturers industry, placing it in the top 25.9%.
Is Alkem Laboratories' 3-Year EBITDA Growth Rate too high?
Alkem Laboratories' current 3-Year EBITDA Growth Rate of 25.40% is 55% above median its 10-year median of 16.40. Over the past 10 years, this metric has ranged from a low of 2.90 to a high of 30.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Alkem Laboratories' value of 25.40% is 185.4% above this industry median. Based on the distribution chart, Alkem Laboratories ranks #209 out of 807 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkem Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #209 out of 807 companies for 3-Year EBITDA Growth Rate. This puts Alkem Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Alkem Laboratories' value of 25.40% is 185.4% above this benchmark. Historically, Alkem Laboratories' own 3-Year EBITDA Growth Rate has ranged from 2.90 to 30.20 over the past decade. While the company's 10-year median is 16.40 vs. the industry median of 8.90, Alkem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current 3-Year EBITDA Growth Rate of 25.40% is 185.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alkem Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current 3-Year EBITDA Growth Rate is 25.40%, which is 55% above median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,209.31, compared to a current price of ₹5,181.00 — trading 16.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 25.40%, which is 55% above median its 10-year median of 16.40 and 185.4% above the Drug Manufacturers industry median of 8.90. Alkem Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current 3-Year EBITDA Growth Rate is 25.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?
Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued.
The current stock price of ₹5,181.00 is trading 16.6% below its estimated GF Value™ of ₹6,209.31.
GuruFocus considers Alkem Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:ALKEM:
3-Year EBITDA Growth Rate: 25.40% (55% above median its 10-year median of 16.40)
GF Value™: ₹6,209.31 vs. price of ₹5,181.00 (16.6% below fair value)
Industry Position: 185.4% above the Drug Manufacturers median (#209 of 807)
No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
96GF Score
Get the complete analysis for NSE:ALKEM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALKEM has been successfully added to your 
